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Postthrombotic morbidity correlates with
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thrombolysis for iliofemoral deep vein
thrombosis
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Bowling Green, Ohio
Background: Iliofemoral deep vein thrombosis (DVT) is associated with severe postthrombotic morbidity when treated
with anticoagulation alone. Catheter-directed thrombolysis (CDT), with or without the addition of mechanical
techniques, is increasingly recommended for patients with iliofemoral DVT, although its effect on postthrombotic
syndrome is not established. This study examined the correlation of residual thrombus with postthrombotic syndrome
after catheter-based attempts at thrombus removal in patients with iliofemoral DVT.
Methods: Seventy-one consecutive patients with iliofemoral DVTwere treated with CDT. Pretreatment and posttreatment
phlebograms were evaluated for quantity of residual thrombus by physicians blinded to clinical patient outcomes.
Postthrombotic syndrome was assessed using CEAP and Villalta scores by examiners blinded to phlebographic results.
Patients were grouped by the amount of residual thrombus in treated vein segments (group 1, <50%; group 2, >50%).
Clinical score and postthrombotic outcomes were plotted vs residual thrombus.
Results: Sixty-three of 71 patients completed CEAP and Villalta analyses. Groups 1 and 2 had median CEAP scores of 1
and 4 (P  .025) and mean Villalta scores of 2.21 and 7.13, respectively (P  .011). There was a direct and significant
correlation of clinical class of CEAPwith residual thrombus (R2 .74; P .004) and a direct linear correlation of Villalta
score with residual thrombus (R2  .61; P  .0014).
Conclusions: In patients with iliofemoral DVT treated with catheter-based techniques of thrombus removal, postthrom-
botic morbidity is related to residual thrombus. When thrombus clearance was complete, the postthrombotic syndrome
was avoided. Residual thrombus is associated with an increasing risk of postthrombotic syndrome. (J Vasc Surg 2012;
55:768-73.)
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cMost patients with acute deep venous thrombosis
(DVT) are treated with systemic anticoagulation.1 Antico-
agulation alone leaves thrombus in situ and relies on en-
dogenous fibrinolytic activity to recanalize the vein. If the
body effectively lyses the clot early in the course of the
disease, venous patency is restored and valve function can
be preserved.2 Furthermore, those who successfully lyse
their clot are less likely to develop recurrent DVT than
patients with persistent thrombus.3-5
Iliofemoral DVT is associated with more severe acute
symptoms and a high risk of postthrombotic syndrome.6-9
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768ostthrombotic syndrome is a debilitating condition that
iminishes quality of life10 and often worsens over time.
he most severe postthrombotic morbidity is found in
atients who have had thrombosis of their iliofemoral ve-
ous segment.6-9 Additionally, the risk of recurrent venous
hromboembolism for patients with iliofemoral DVT is
ignificantly higher than patients with infrainguinal DVT,11
urther escalating the likelihood and severity of their post-
hrombotic morbidity.7,12
Strategies of thrombus removal have been selectively of-
ered to patients with extensive DVT in an attempt to reduce
ostthrombotic morbidity. Catheter-directed thrombolysis
CDT) has evolved as the management strategy of choice if
hrombus removal is desired.Observational studies have dem-
nstrated early success rates in the 70% to 90% range.13-16
Avoidance of postthrombotic morbidity is the goal of
ny strategy of thrombus removal, yet it has not been
bjectively measured by validated outcome instruments in
tudies published to date. As there is often a range of
hrombus clearance, it would be instructive to know if the
egree of lysis (or the amount of residual thrombus) at the
ompletion of CDT or pharmacomechanical thrombolysis
orrelates with postthrombotic morbidity.
The purpose of this study was to objectively assess the
ostthrombotic outcome of patients treated with catheter-
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Volume 55, Number 3 Comerota et al 769based methods of thrombus removal to determine if
postthrombotic morbidity correlates with residual throm-
bus at the completion of their catheter-based intervention.
METHODS
Seventy-one consecutive patients with symptomatic
acute DVT involving the iliofemoral venous segment, with
or without involvement of the vena cava or infrainguinal
segments, who were treated with CDT and/or pharmaco-
mechanical thrombolysis, form the basis of this study. All
patients were ambulatory, had a life expectancy of at least 2
years, and did not have an absolute contraindication to
thrombolytic therapy. Three patients had known ipsilateral
chronic venous disease before their acute iliofemoral DVT.
This study was approved by the institutional review board
and all patients signed an informed consent. All patients
were treated within 20 days of symptom onset, with a mean
of 4.5 days (range, 2-20 days) of onset.
DVT was initially diagnosed with a duplex ultrasound
scan and confirmed with ascending phlebography. Access
for CDT was obtained with ultrasound scan guidance into
the ipsilateral popliteal vein, common femoral vein, and/or
posterior tibial vein, depending on the location and extent
of thrombosis. A pretreatment vena cavogram was per-
formed in all patients to assess whether thrombus involved
the vena cava. If the vena cava contained nonocclusive,
free-floating thrombus, a vena caval filter was placed before
catheter-based intervention. Otherwise, optional vena caval
filters were used at the discretion of the interventionalist.
After confirmatory phlebography, the thrombosed ve-
nous segments were traversed with a 0.35-inch guide-
wire. Multiside-hole catheters (UniFuse; AngioDynamics,
Latham, NY) were used for drip infusion of the lytic agents,
and the Trellis (Covidien, Santa Clara, Calif), AngioJet
(Medrad, Minneapolis, Minn), and EKOS Lysus (EKOS
Corp, Bothell, Wash) catheters were used for pharmacom-
echanical thrombolysis. Before the availability of pharma-
comechanical techniques, CDT with drip infusion was
used. When pharmacomechanical techniques became avail-
able, these were used initially. If thrombus remained after
pharmacomechanical treatment, CDT was then performed
to lyse residual thrombus.
Patients were treated with recombinant tissue plasmin-
ogen activator (rt-PA) at a dose of 1 to 2mg/hour depend-
ing on the volume of thrombus and the number of cathe-
ters used. In patients who had multiple catheters (ie,
popliteal and posterior tibial access or those treated for
bilateral DVT), a dose of 1.5 to 2 mg/hour was used. The
rt-PA was infused at a concentration of 1 mg/50 mL to 1
mg/100 mL, and treatment duration ranged from 1.5 to
94 hours (mean, 37 hours).
Serial phlebography was obtained to monitor throm-
bus resolution after each run of the Trellis and AngioJet
catheters and after every 12 to 16 hours of thrombolysis,
with either drip infusion or the EKOS catheter. After lysis,
areas of infrainguinal (femoral vein) venous stenoses were
dilated with balloon catheters, and iliac vein stenoses were
treated with venoplasty and stenting to provide unob- btructed venous drainage from the common femoral vein
nto the vena cava. Common iliac veins were treated with
4- to 16-mm stents, with a portion of the stent adjacent to
he flow divider extending into the vena cava and external
liac veins with 12- to 14-mm stents. If a stent was extended
nto the common femoral vein, it was kept cephalad to the
aphenofemoral junction. Stents were not used in infrain-
uinal veins.
The posttreatment phlebogram (after lysis, balloon di-
ation, and stenting) was analyzed to determine the amount
f residual clot compared to the pretreatment phlebogram
sing a modification of the venous scoring method de-
cribed by Mewissen et al13 and reported by Martinez et
l.17 Briefly, nine venous segments (inferior vena cava,
ommon iliac, external iliac, common femoral, proximal
emoral, distal femoral, popliteal, tibial, and profunda fem-
ris veins) were evaluated and scored as follows: 0, throm-
us-free (normal) segment; (1) 1% to 49% luminal reduc-
ion by thrombus and/or stenosis; (2) 50% to 99% luminal
eduction; and (3) occluded. The percent of clot lysed was
alculated by subtracting the posttreatment thrombus
core from the pretreatment thrombus score and dividing
y the pretreatment score. The physicians interpreting the
hlebograms were blinded to the clinical outcomes of the
atients. The physicians performing the clinical evaluation
f the patients were blinded to the phlebographic results.
After catheter-based intervention, patients were antico-
gulated with intravenous unfractionated heparin or low-
olecular-weight heparin and converted to warfarin to a
arget international normalized ratio of 2.5. The duration
f anticoagulation was in accordance with the American
ollege of Chest Physicians’ guidelines1 at a minimum,
ith many extended beyond 1 year. All patients were
rescribed 30 to 40 mm Hg ankle-gradient compression
tockings and were instructed to wear them from the time
hey got out of bed in the morning to the time they
eturned to bed at night.
Patients were examined as part of a systematic fol-
ow-up in which they returned at 2 weeks, 1 month, 3
onths, 6 months, and 12 months postdischarge, and
very 6months thereafter. The reported outcomes are from
heir last encounter. Patients’ CEAP clinical classification
nd Villalta scores were recorded. The CEAP clinical clas-
ification system is based on clinical classification, etiology,
natomical distribution, and pathophysiology of venous
isease.18 This study focused on the clinical class of the
atient: C0, no evidence of venous disease; C1, reticular
eins; C2, varicose veins; C3, edema; C4, pigmentation;
5, healed venous ulcers; and C6, active venous ulcer.
The Villalta scale consists of five patient-related venous
ymptoms (pain, cramps, heaviness, paresthesia, and pruri-
us) and six clinician-assessed physical signs (pretibial
dema, skin induration, hyperpigmentation, venous ecta-
ia, redness, and pain during calf compression), which are
ated on a four-point scale: 0, none; 1, mild; 2, moderate;
nd 3, severe. Points are summed to produce a total score
range, 0-33). Patients were classified as having postthrom-
otic syndrome if their score was5 or if a venous ulcer was
.
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March 2012770 Comerota et alpresent in a leg with previous DVT. The postthrombotic
syndrome is classified as mild if the Villalta score is 5 to 9,
moderate if the score is 10 to 14, and severe if the score is
15 or if a venous ulcer is present.19 The Villalta scale has
been validated and is reported to be a reliable method of
identifying and quantifying the postthrombotic syn-
drome.19
After analysis of the entire patient cohort, patients were
divided into two groups based on their percentage of clot
lysis—group 1 were patients who had 50% residual clot,
and group 2 were those with 50% residual clot—to de-
termine if there was a difference in group-related outcomes.
To evaluate if a more direct correlation existed between
postthrombotic morbidity and residual thrombus, each
patient’s clinical classification of CEAP and Villalta scores
were plotted vs residual thrombus at the completion of lytic
therapy.
Statistical analysis. The t statistic test was used to test
the population mean score difference between the two
groups. The CEAP and Villalta scores in each group are
compared using the exact Wilcoxon test statistic. The R-
square between the outcome variable (CEAP or Villalta
score) and clot lysis is based on the linear trend for 10%
range of clot lysis vs the mean outcome score of the
corresponding range.
RESULTS
The mean age of the patients was 45 years. Thirty-two
(45%) patients were women (mean age, 35 years), and 39
were men (mean age, 52 years). Twenty-three patients had
a vena cava filter inserted pretreatment. Mean duration of
follow-up was 18.9 months; overall clot lysis was 79%
(mean). Mean clot lysis for group 1 was 42% and mean clot
lysis for group 2 was 85%.
Sixty-four patients completed the CEAP and Villalta
analyses. Three patients known to have chronic venous
disease before their DVTwere considered outliers and were
excluded from this analysis. Three other patients died and
one patient was lost to follow-up.
At follow-up, the mean CEAP clinical classification was
1.3 and the mean Villalta score was 3.81 for all patients.
Group 1 had a median CEAP clinical classification score of
1 and group 2 had a median score of 4 (P  .025). The
mean Villalta scores for group 1 and group 2 were 2.21 and
7.13, respectively (P  .0032; Table 1).
Fig 1 plots the CEAP clinical classification score vs
percent of residual thrombus for each patient, demonstrat-
ing a direct linear correlation of CEAP clinical classification
Table I. CEAP and Villalta scores of patients per group
CEAP
(median)
Villalta
(mean)
Group 1 (50% residual thrombus) 4 7.13
Group 2 (50% residual thrombus) 1 2.21
P value .025 .011score at follow-up with residual thrombus (R2  .74; P  p0014). Fig 2 plots the Villalta score vs residual thrombus
or each patient, illustrating a direct linear correlation of
illalta score with lytic success (R2  .61; P  .0032). A
0% regression trend was used; for every 10% increase in
lot lysis, there was a decrease in the Villalta score of 1.33.
atients who had 90% lysis had few clinical findings and
nly three had a Villalta score 5, indicating that 15 of 18
83%) were free of postthrombotic symptoms, and the
hree patients with postthrombotic changes hadmild symp-
oms (Villalta scores of 5 or 6).
Complications. There were five major complications
esulting fromCDT: three patients had major bleeding and
wo developed acute renal failure. One bleeding complica-
ion was a retroperitoneal hematoma occurring suddenly
n postprocedural day 6 while the patient was on systemic
nticoagulation. This patient required operative decom-
ression. Two puncture site hematomas required operative
ecompression. Four minor bleeding complications were
uncture site hematomas, requiring a 1- to 2-unit blood
ransfusion, and each resolved without operative decom-
ig 1. Plot of clinical class of CEAP at follow-up vs residual
hrombus at treatment end. Data points may represent more than
ne patient.
ig 2. Plot of Villalta score at follow-up vs residual thrombus at
reatment end. Data points may represent more than one patient.ression. Two patients who were treated for extensive
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Volume 55, Number 3 Comerota et al 771iliofemoral and vena caval thrombosis developed nonoligu-
ric acute renal failure, both of whom had treatment times
exceeding 50 hours, large contrast loads, and hemoglobin-
uria after rheolytic pharmacomechanical thrombolysis.
Both recovered normal renal function.
DISCUSSION
The results of this study demonstrate that, in patients
with iliofemoral DVT treated with CDT or pharmacom-
echanical thrombolysis, there is a direct correlation of post-
thrombotic morbidity with residual thrombus at treatment
end. The greater the residual thrombus after catheter-
directed thrombolysis, the worse the patients’ clinical clas-
sification score and the higher their Villalta score. These
results demonstrate that when a high degree of clot lysis is
achieved, and rethrombosis is avoided, patients have mini-
mal sequelae of the postthrombotic syndrome. Further-
more, the implications of these observations are that phy-
sicians who embark on a strategy of thrombus removal to
treat patients with extensive DVT should persist until the
thrombus is removed and resist terminating treatment
early, leaving a thrombus burden behind. Patients will
recognize substantial benefit, as 83% patients (15 of 18)
with10% residual thrombus were free of postthrombotic
syndrome, and only three patients with 10% residual
thrombus had mild symptoms (Villalta scores of 5 and 6).
The CEAP classification was designed to standardize
reporting of patients with venous disease by providing an
accurate snapshot of their condition. While it is thought of
as a categorical variable, the clinical class of CEAP is respon-
sive to treatment, as varicose veins, edema, pigmentation,
and ulceration are part of postthrombotic morbidity and
their findings correlate with treatment.
The iliofemoral venous segment is the single venous
outflow channel for the lower extremities. When it be-
comes occluded with thrombus, patients’ symptoms are
often severe. If iliofemoral DVT is accompanied by infrain-
guinal thrombosis, patients’ symptoms may escalate. This
causes high venous and compartment pressures acutely,20
which often persist as chronic venous hypertension, the
basic pathophysiology of postthrombotic morbidity.21
Patients with iliofemoral DVT treated with anticoagu-
lation alone develop severe postthrombotic morbidity.6,8,9
It has been suggested that the threat of postthrombotic
morbidity several years from the acute event may not be
sufficient to convince patients to undergo or physicians to
recommend a strategy of thrombus removal.22 However,
patients with iliofemoral DVT are continuously symptom-
atic. Their postthrombotic morbidity is not delayed by
years, but it is generally continuous from the time of the
acute event. Kahn et al7 studied the frequency and time
course of the postthrombotic syndrome in patients with
acute symptomatic DVT using the Villalta scale as the
outcome measure. They reported that the best indepen-
dent predictor of the postthrombotic syndrome over time
was a patient’s 1-month symptom score. The most impor-
tant predictor of severe postthrombotic morbidity was
thrombosis of the common femoral or iliac veins (odds flatio, 2.23).7 Kahn’s findings are in agreement with our
bservations and those reported by others that iliofem-
ral DVT is associated with the most severe pos-
thrombotic morbidity.
Others have shown that, in patients with proximal DVT
reated with anticoagulation alone, there is a strong rela-
ionship of residual thrombus score and venous outflow
esistance at 3 months.23 Venous outflow resistance trans-
ates into venous hypertension, which is the underlying
athophysiology of chronic venous disease. These authors
oncluded that a lack of recanalization after the thrombotic
pisode is an important predictor of the postthrombotic
yndrome.
Early results of two randomized trials of CDT vs anti-
oagulation alone have been reported. Elsharawy and El-
ayat24 calculated that they would need 30 patients to show
50% difference in outcome with a significance level of
.05 at a power of 90% when treating iliofemoral patients
ith DVT with thrombolysis. They randomized 35 pa-
ients to CDT plus anticoagulation or anticoagulation
lone. At 6 months, the patency rate with thrombolysis was
2% vs 12% with anticoagulation (P .001). Venous valve
eflux was preserved in 89% of patients undergoing throm-
olysis vs 59% in patients treated with anticoagulation
lone (P  .04).
Enden et al25 reported preliminary results of 103 pa-
ients with iliofemoral DVT randomized to CDT or anti-
oagulation as part of the Catheter-directed Venous
hrombolysis in Acute Iliofemoral Vein Thrombosis
CaVenT) study. Their target was to randomize 200 pa-
ients and to report the postthrombotic syndrome at 2
ears. In their 6-month interim analysis of 103 patients,
liofemoral patency was found in 64% of the thrombolysis
roup compared to 36% of the anticoagulation group (P
004). Physiological venous obstruction was observed in
0% of the thrombolysis group vs 49% of the anticoagula-
ion patients (P  .004). Valve function did not differ
etween groups. Because an occluded vein cannot reflux,
alve incompetence may worsen over time in the anticoag-
lation group if partial recanalization occurs.
A nonrandomized single-center study reported 6-year
utcomes of 103 patients treated with CDT for iliofemoral
VT.16 Eighty-two percent of the limbs had patent veins
nd competent valves with no evidence of skin change or
enous claudication.
The studies described in the previous paragraphs used
nly catheter-directed drip infusion of lytic agents. Phar-
acomechanical techniques seem to improve the efficacy of
hrombus clearance.26,27 Martinez et al17 reported a se-
uential experience with isolated segmental pharmaco-
echanical thrombolysis vs catheter-directed thromboly-
is, demonstrating that the pharmacomechanical approach
esulted in more efficient overall thrombus removal, with
horter treatment times and lower doses of plasminogen
ctivator.
The use of a variety of pharmacomechanical tech-
iques, using lower doses of rt-PA in larger volumes of
uid, correction of underlying venous lesions with veno-
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have all contributed to improved outcomes over time.
Patients are treated today more efficiently, have shorter
treatment times, receive lower doses of plasminogen acti-
vators, and have better overall outcomes than patients
treated years earlier.
An important but often unrecognized consequence of
iliofemoral DVT is the increased risk of recurrence. Patients
with iliofemoral DVT treated with anticoagulation alone
have a 2.4-fold risk of recurrence during the first 3 months
of therapy, which is similar in magnitude to patients with
malignancy.11 Baekgaard et al16 found that only 6% of
patients treated with CDTdeveloped recurrence during the
6-year follow-up, suggesting that successful thrombus
elimination with restoration of vein patency reduces the
high recurrence rate, thereby further reducing the risk of
postthrombotic morbidity.
Investigators have established the relationship of recur-
rence with persistent thrombus after an episode of acute
proximal DVT.4,5 A recent systematic review using phlebo-
graphic criteria showed an inverse correlation between
thrombus regression and recurrent venous thromboembo-
lism.28 It has been our observation that patients success-
fully treated with CDT have fewer recurrences than those
with larger residual thrombus burdens.29 This raises the
interesting and attractive possibility that a successful strat-
egy of thrombus removal will diminish the risk of recur-
rence.
Restoring patency to the thrombosed vein and preserv-
ing valve function are considered surrogate outcomes com-
pared to objective measures of the postthrombotic syn-
drome. Whereas objective measures of postthrombotic
morbidity are always desirable in follow-up studies, such as
those reported in this article, it is reasonable to expect that
serious postthrombotic morbidity will be avoided in pa-
tients with normally patent veins with functional valves.
A limitation of this study was that it was a retrospective
analysis with no randomized control group of patients
treated with anticoagulation alone. A number of patients
were referred for treatment after failed initial therapy with
anticoagulation (severe persistent pain and swelling) or
failed attempts at CDT. Therefore, the outcomes observed
here may not represent those expected in a nonreferral
practice.
The strengths of this study were that all patients with
iliofemoral DVT who were treated with CDT or pharma-
comechanical thrombolysis were included in this analysis.
All had complete pretreatment and posttreatment phlebog-
raphy and objective evaluation of postthrombotic morbid-
ity. The phlebographic interpretations were performed by
individuals blinded to patient outcomes, and the physicians
evaluating patients were blinded to the phlebographic re-
sults. This seems to be the first report of a correlation of
validated outcome measures of postthrombotic morbidity
with phlebographic results after a catheter-based strategy of
thrombus removal.
We are hopeful that, as more information is gathered
on the benefit of strategies of thrombus removal for pa-ients with iliofemoral DVT, treatments designed to elim-
nate thrombus, restore patency, and preserve valve func-
ion will be adopted. This should result in less
ostthrombotic morbidity and improved quality of life for
atients. A large, prospective, National Institutes of
ealth-funded study, the Acute Venous Thrombosis:
hrombus Removal with Adjunctive Catheter-Directed
hrombolysis trial, is now underway and will provide im-
ortant information in this area.30,31 Nearly 700 patients
ith iliofemoral and infrainguinal DVT will be stratified by
roximal extent of thrombus and randomized to CDT plus
nticoagulation or anticoagulation alone. Outcomes will
ocus on objective measures of postthrombotic morbidity,
imilar to those reported in this study. The Acute Venous
hrombosis: Thrombus Removal with Adjunctive Cathe-
er-Directed Thrombolysis trial, by its randomized and
tratified study design, will help answer the important ques-
ion of whether eliminating thrombus with catheter-based
echniques is an important adjunct to anticoagulation in
he management of patients with acute femoropopliteal
nd iliofemoral DVT.
Whenever possible, patients should be randomized in
ell-designed studies addressing whether a strategy of
hrombus removal is beneficial compared with anticoagu-
ation alone. However, in the absence of a randomized trial,
urrent evidence suggests that eliminating thrombus from
he iliofemoral system restores patency,13,32-34 preserves
alve function,16 improves quality of life,35,36 and reduces
ostthrombotic morbidity.
Our results show that, in patients with iliofemoral DVT
reated with catheter-based techniques of thrombus re-
oval, there is a direct correlation of postthrombotic mor-
idity with residual thrombus.
The authors acknowledge the editorial assistance of
arilyn Gravett in the preparation of this manuscript.
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